HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The efficacy of monatepil, a new calcium antagonist, in the treatment of essential hypertension.

Abstract
A multicenter, open-label trial in Japan examined the efficacy, safety, and optimal dose of monatepil (AJ-2615) as monotherapy and in combination therapy with angiotensin-converting enzyme (ACE) inhibitors or beta-blockers. Patients with essential hypertension who had never been treated or had been refractory to conventional antihypertensive agents were enrolled in the trial. During a 4-week control period patients assigned to monotherapy received placebo and those assigned to combination therapy received an ACE inhibitor or beta-blocker and placebo. Patients with systolic blood pressure (BP) > or = 160 mm Hg and diastolic BP > or = 95 mm Hg at the end of the control period were enrolled in the study. The initial dose of monatepil was 30 mg/day in monotherapy and 15 mg/day in combination therapy; the daily dose was titrated to 60 mg/day according to the antihypertensive response. The treatment period was 8 to 12 weeks. Blood pressure decreased from 168 +/- 8/100 +/- 6 to 142 +/- 9/85 +/- 7 mm Hg (SD) with monatepil monotherapy, from 171 +/- 11/102 +/- 6 to 141 +/- 9/84 +/- 6 mm Hg in combination with ACE inhibitors, and from 175 +/- 13/102 +/- 7 to 153 +/- 21/91 +/- 9 mm Hg in combination with beta-blockers (P < .001). When patients in whom mean BP decreased by > or = 13 mm Hg were defined as responders, the response rate was 80.4%, 78.1%, and 51.6% in the respective groups.(ABSTRACT TRUNCATED AT 250 WORDS)
AuthorsM Ishii, O Iimura, K Yoshinaga, K Abe, Y Inagaki, S Yagi, K Kuramoto, N Kajiwara, T Saruta, M Kuramochi
JournalAmerican journal of hypertension (Am J Hypertens) Vol. 7 Issue 10 Pt 2 Pg. 141S-145S (Oct 1994) ISSN: 0895-7061 [Print] United States
PMID7826564 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Adrenergic beta-Antagonists
  • Calcium Channel Blockers
  • Dibenzothiepins
  • Piperazines
  • Cholesterol
  • Peptidyl-Dipeptidase A
  • monatepil
Topics
  • Adrenergic beta-Antagonists (administration & dosage, therapeutic use)
  • Adult
  • Aged
  • Blood Pressure (drug effects)
  • Calcium Channel Blockers (administration & dosage, therapeutic use)
  • Cholesterol (blood)
  • Dibenzothiepins (administration & dosage, therapeutic use)
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hypertension (blood, drug therapy)
  • Male
  • Middle Aged
  • Peptidyl-Dipeptidase A (administration & dosage, therapeutic use)
  • Pilot Projects
  • Piperazines (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: